138 Results for "

cAMP/PKA

" in MedChemExpress (MCE) Product Catalog:
Products (138)

138 Results for "cAMP/PKA" in MCE Product Catalog:

  • Targets Recommended:
49
49 Publications Verification
Art. -Nr.: HY-B0764
CAS. Nr.: 16980-89-5
Synonyms: Dibutyryl cAMP sodium; DBcAMP sodium
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
loading...
    loading...
49
49 Publications Verification
Art. -Nr.: HY-B0764A
CAS. Nr.: 938448-87-4
Synonyms: Dibutyryl cAMP hemicalcium; DBcAMP hemicalcium
Bucladesine (Dibutyryl cAMP; DBcAMP) hemicalcium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
loading...
    loading...
39
39 Cited Publications
Art. -Nr.: HY-12306
CAS. Nr.: 76939-46-3
Reinheit:  99.91%
Synonyms: 8-Br-cAMP sodium salt
Target:  

PKA Apoptosis

Forschungsgebiete:  

Cancer

8-Bromo-cAMP sodium (8-Br-Camp) sodium salt, a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP sodium salt has anti-proliferative and apoptotic effects against cancer cells .
loading...
    loading...
39
39 Cited Publications
Art. -Nr.: HY-12306A
CAS. Nr.: 23583-48-4
Reinheit:  99.48%
Synonyms: 8-Br-cAMP
Target:  

PKA Apoptosis

Forschungsgebiete:  

Cancer

8-Bromo-cAMP (8-Br-Camp), a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP has anti-proliferative and apoptotic effects against cancer cells .
loading...
    loading...
31
31 Cited Publications
Art. -Nr.: HY-13749
CAS. Nr.: 486460-32-6
Reinheit:  99.75%
Synonyms: MK-0431
Sitagliptin (MK-0431) is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes .
loading...
    loading...
31
31 Cited Publications
Art. -Nr.: HY-13749A
CAS. Nr.: 654671-78-0
Reinheit:  99.79%
Synonyms: MK-0431 phosphate
Sitagliptin (MK-0431) phosphate is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes .
loading...
    loading...
31
31 Cited Publications
Art. -Nr.: HY-13749B
CAS. Nr.: 654671-77-9
Reinheit:  99.83%
Synonyms: MK-0431 phosphate monohydrate
Sitagliptin (MK-0431) phosphate monohydrate is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin phosphate monohydrate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate monohydrate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate monohydrate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate monohydrate can be used for the study of 1-type and 2-type diabetes .
loading...
    loading...
6
6 Cited Publications
Art. -Nr.: HY-100530D
CAS. Nr.: 142439-94-9
Reinheit:  99.69%
Target:  

PKA

Forschungsgebiete:  

Neurological Disease

Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS sodium salt is resistant to hydrolysis by phosphodiesterases .
loading...
    loading...
6
6 Cited Publications
Art. -Nr.: HY-100530
CAS. Nr.: 151837-09-1
Reinheit:  99.53%
Target:  

PKA

Forschungsgebiete:  

Neurological Disease

Rp-cAMPS triethylammonium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS triethylammonium salt is resistant to hydrolysis by phosphodiesterases .
loading...
    loading...
5
5 Cited Publications
Art. -Nr.: HY-P1290
CAS. Nr.: 121932-06-7
Synonyms: PKI-(6-22)-amide
Target:  

PKA

Forschungsgebiete:  

Neurological Disease

PKA Inhibitor Fragment (6-22) amide is a highly potent and specific competitive inhibitor of PKA, with Ki values of 1.7 nM and 1.6 nM against human and bovine PKA catalytic subunits, respectively. The IC50 of PKA Inhibitor Fragment (6-22) amide targeting bovine PKA is 8.6 nM. PKA Inhibitor Fragment (6-22) amide effectively abolishes PKA activity in mouse brain and spinal cord, and exerts in vivo efficacy via intracerebroventricular administration. PKA Inhibitor Fragment (6-22) amide significantly reverses low-dose morphine analgesic tolerance in mice and blocks photoaffinity labeling of cAMP-dependent protein kinase. PKA Inhibitor Fragment (6-22) amide can be applied to research in fields related to the mechanism of morphine analgesic tolerance and skin wound healing .
loading...
    loading...
5
5 Cited Publications
Art. -Nr.: HY-P1290A
Synonyms: PKI-(6-22)-amide TFA
Target:  

PKA

Forschungsgebiete:  

Neurological Disease

PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent protein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse antinociceptive tolerance in mice .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-P1291
CAS. Nr.: 201422-03-9
PKI 14-22 amide, myristoylated is a selective, cAMP-dependent, competitive PKA inhibitor with Ki=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated can prevent the development of morphine analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated can be used in research fields such as opioid tolerance mechanisms and antiviral drugs .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-P0222
CAS. Nr.: 99534-03-9
Target:  

PKA

Forschungsgebiete:  

Others

PKI(5-24) is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase), with a Ki of 2.3 nM. PKI(5-24) corresponds to residues 5-24 in the naturally occurring heat-stable protein kinase inhibitor .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-P1291A
PKI 14-22 amide, myristoylated TFA is a selective, cAMP-dependent, competitive PKA inhibitor with Ki=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated TFA makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated TFA can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated TFA can prevent the development of analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated TFA can be used in research fields such as opioid tolerance mechanisms and antiviral drugs .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-B0327
CAS. Nr.: 57381-26-7
Synonyms: Dicloguamine
Irsogladine (Dicloguamine) is an orally active gastric mucosal protective agent. Irsogladine inhibits breast cancer recurrence and lung metastasis in nude mice . Irsogladine inhibits the transcriptional activities of NF-κB and AP-1, suppresses the activities of PDE and PDE4 to elevate intracellular cAMP levels, and activates TRPV1 and KATP channels. Irsogladine enhances iNOS expression, NO production, and the activation of cAMP-responsive elements. Irsogladine inhibits the development and progression of intestinal polyps in Apc-mutant mice. Irsogladine alleviates oxidative stress, increases gastric mucosal blood flow, and stimulates the production of endogenous prostaglandins. Irsogladine promotes insulin secretion in MIN6 cells. Irsogladine inhibits tumor angiogenesis, cancer cell proliferation, and the production of proinflammatory cytokines. Irsogladine exerts protective effects on astrocytes in ethanol/hydrochloric acid-induced gastric ulcers in mice. Irsogladine prevents colitis in IL-10 gene-deficient mice by reducing the production of IL-12 and IL-23. Irsogladine upregulates gap junction intercellular communication in pancreatic cancer cells via the PKA pathway. Irsogladine is applicable to research related to breast cancer, intestinal polyposis, gastric ulcer, spontaneous colitis, glioma, liver cancer, and pancreatic cancer [5][6] .
loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-108618
CAS. Nr.: 686770-80-9
Reinheit:  99.42%
Forschungsgebiete:  

Endocrinology

BC11-38 is a potent, selective, and biologically active PDE11 inhibitor, with IC50s of 0.28 µM and >100 µM for PDE11 and PDE1-10, respectively. BC11-38 elevates cAMP levels, PKA-mediated ATF-1 phosphorylation, and cortisol production in H295R cells .
loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-128358
CAS. Nr.: 2374703-19-0
Reinheit:  98.37%
Forschungsgebiete:  

Neurological Disease

MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC50 of 1.2 μM .
loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-110218
CAS. Nr.: 1134613-19-6
Reinheit:  98.15%
Forschungsgebiete:  

Others

CW 008, a derivative of pyrazole-pyridine, is a CREB or PKA pathway agonist. CW 008 also is a stem cell differentiating agent. CW 008 stimulates osteoblast differentiation of human MSCs and increases bone formation in ovariectomized mice. CW008 promotes osteogenesis by activating cAMP/PKA/CREB signaling pathway and inhibiting leptin secretion .
loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-P80847
Synonyms: PRKAR2A; PKR2; PRKAR2; cAMP-dependent protein kinase type II-alpha regulatory subunit

Host:  

Rabbit

Application:  

WB, IHC-P, ICC/IF, IP

Reactivity:  

Human, Mouse, Rat, Pig

loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-N2118
CAS. Nr.: 521-32-4
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .
loading...
    loading...